An Optimistic Approach
Laura Hagerty, Ph.D. As we settle into 2016 and face a fresh new year full of hope and optimism, much of the focus of our DMD community remains on the exon skipping therapy at the regulatory review end of the development pipeline: Sarepta Therapeutics’ eteplirsen. In November we saw our first advisory committee review for . . .